Decipher Prostate Genomic Classifier
Use
The Decipher Prostate Genomic Classifier is a 22-gene expression test designed to provide prognostic information for prostate cancer patients. It helps physicians in making informed treatment decisions by clarifying the risk of metastasis within the next five years. The test is validated across a spectrum of localized prostate cancer and its results are used to tailor treatment plans, potentially recommending less or more intensive treatment based on the assessed risk.
Special Instructions
The test is performed on tissue samples obtained during biopsy or surgical removal of the prostate. The test is covered by Medicare and private insurers and is available in the US as part of Veracyte's CLIA-validated laboratory developed test (LDT) service.
Limitations
While the Decipher Prostate Genomic Classifier provides valuable prognostic information, it is not cleared or approved by the FDA and should be used as part of a broader clinical assessment. Clinical decisions should not rely solely on the test results and should consider the overall clinical picture.
Methodology
NGS (WTS)
Biomarkers
Result Turnaround Time
7-14 days
Related Documents
For more information, please review the documents below
Specimen
Tissue (FFPE)
Volume
Not provided
Minimum Volume
Not provided
Collection Instructions
Obtain tissue samples during biopsy or surgical removal of the prostate.